P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability-Reference-Cited by-同舟云学术

P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability

Published:2019-07-22 Issue:9 Volume:16 Page:3842-3852
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Martínez-Chávez Alejandra¹²^ORCID,van Hoppe Stéphanie¹^ORCID,Rosing Hilde²,Lebre Maria C.¹,Tibben Matthijs²,Beijnen Jos H.¹²³,Schinkel Alfred H.¹^ORCID

Affiliation:

1. Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

2. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

3. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

Funder

Consejo Nacional de Ciencia y Tecnolog?a

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.9b00475

Reference42 articles.

1. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib

2. Expanding ribociclib use

3. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors